Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder.

@article{Chang2017MyastheniaGA,
  title={Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder.},
  author={Elaine J. Chang and Anita L. Sabichi and Yvonne H Sada},
  journal={Journal of immunotherapy},
  year={2017},
  volume={40 3},
  pages={
          114-116
        }
}
Checkpoint inhibitors have become standard therapy for multiple cancers, and their use will increase in the next year as regulatory approvals for additional indications are expected. It is essential for clinicians to be aware of the potential for rare immune-related adverse effects. Here, we report the case of a new diagnosis of myasthenia gravis (MG) after the use of nivolumab for squamous cell carcinoma of the bladder. A review the literature identified 10 cases of MG diagnosed after… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): results from the phase I/II CheckMate 032 study

  • P Sharma, P Bono, JW Kim
  • J Clin Oncol
  • 2016

Similar Papers

Loading similar papers…